Focus: Bracco is a 97-year-old Italian diagnostic imaging company with 1,001-5,000 employees, specializing in contrast agents and imaging solutions for cardiovascular, gastroenterology, and hematology applications. As a mid-cap biotech with established market presence, Bracco operates a mature but stable imaging portfolio.
Profile data last refreshed 9h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Bracco to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
One of two peak-stage products representing core revenue base in GI imaging.
Help build intelligence for Bracco
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Bracco's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Peak-stage formulation in dysphagia assessment; part of diversified barium sulfate portfolio.
Peak-stage barium sulfate variant addressing patient tolerance in GI imaging.
Radioactive tracer for cardiac viability assessment; nearing patent expiration.
Historic contrast product in LOE_APPROACHING stage; represents legacy portfolio erosion.
41 discontinued, 23 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo